Article

Neutralization of recent SARS-CoV-2 variants by genetically and structurally related mAbs of the pemivibart lineage

2024-11-13

Abstract excerpt

Pemivibart is a monoclonal antibody therapy currently under Emergency Use Authorization for the for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents over 12 years of age with certain immunocompromised conditions. As a part of the overall monitoring strategy for the activity of pemivibart, the antibody is regularly evaluated against emerging variants of SARS-CoV-2 using...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c692784a-b880-5eee-92f2-b297784b6514
DOI: 10.1101/2024.11.11.623127

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Neutralization of recent SARS-CoV-2 variants by genetically and structurally related mAbs of the pemivibart lineageDOI 10.1101/2024.11.11.623127Read

Pemivibart is less active against recent SARS-CoV-2 JN.1 sublineagesSemantic proximity Read

VYD2311 is a promising candidate for passive immunization against COVID-19 in immunocompromised individualsSemantic proximity Read

Escape of SARS-CoV-2 variants KP1.1, LB.1 and KP3.3 from approved monoclonal antibodiesSemantic proximity Read

Immunobridging Analysis of Pemivibart for the Treatment of COVID-19 – A Therapeutic Gap for the Immune Compromised RemainsSemantic proximity Read

Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutationsSemantic proximity Read

Dynamics of SARS-CoV-2 variants and mutations in Central Sweden between 2023 and 2024 and their potential implications on monoclonal antibodies pemivibart and sipavibart as PrEP in the region.Semantic proximity Read

Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical TrialSemantic proximity Read

In vivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential.Semantic proximity Read

Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5Semantic proximity Read

Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In VitroSemantic proximity Read

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy.Semantic proximity Read

Omicron variant escapes therapeutic mAbs contrary to eight prior main VOCSemantic proximity Read